Lamivudine/nevirapine/stavudine

From Wikipedia, the free encyclopedia
Lamivudine/nevirapine/stavudine
Combination of
Lamivudinenucleoside reverse transcriptase inhibitor
Nevirapinenon-nucleoside reverse transcriptase inhibitor
Stavudinenucleoside reverse transcriptase inhibitor
Clinical data
Trade namesTriomune, others
ATC code
Identifiers
CAS Number
ChemSpider
  • none

Lamivudine/nevirapine/stavudine (3TC/NVP/d4T) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS.[1] It contains lamivudine, nevirapine, and stavudine.[1] It is either used by itself or along with other antiretrovirals.[1] It is taken by mouth twice a day.[1]

It is on the World Health Organization's List of Essential Medicines.[2] As of 2015, it is not commercially available in the United States.[3]

Medical uses[]

It is a common first line treatment in the developing world.[4]

Adverse effects and safety[]

The medication is generally well tolerated.[5] Side effects are those of the underlying medications.[1] This may include rash, numbness, pancreatitis, and high blood lactate levels.[5] Use is not recommended in those with significant liver problems.[5] It is unclear if use in pregnancy is safe for the baby and recommendations include starting in the second trimester if possible.[5]

References[]

  1. ^ a b c d e World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 160. hdl:10665/44053. ISBN 9789241547659.
  2. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  3. ^ Kasper, Dennis L.; Fauci, Anthony S.; Hauser, Stephen; Longo, Dan; Jameson, J. Larry; Loscalzo, Joseph (2015). Harrison's Principles of Internal Medicine 19/E (Vol.1 & Vol.2). McGraw Hill Professional. p. 1277. ISBN 9780071802161. Archived from the original on 2016-12-20.
  4. ^ Siegfried, NL; Van Deventer, PJ; Mahomed, FA; Rutherford, GW (19 April 2006). "Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults". The Cochrane Database of Systematic Reviews. 2011 (2): CD004535. doi:10.1002/14651858.CD004535.pub2. PMC 8407055. PMID 16625606.
  5. ^ a b c d "Nevirapine/stavudine/lamivudine" (PDF). aidsmap. Archived from the original (PDF) on 20 December 2016. Retrieved 18 December 2016.

External links[]

Retrieved from ""